Point Of Care Diagnostics Market (2026 - 2035) Size, Share And Trend Analysis Report By Region And Segmentation Forecasts

What is the Global Point of Care Diagnostics Market Size?

The point of care diagnostics market size is estimated to grow from USD 1.78 billion in 2024 to reach USD 1.98 billion in 2025 and USD 5.29 billion by 2035, representing a CAGR of 10.3% during the forecast period.

To learn more about this report, request a free sample copy

Owing to the need for better diagnostic tools with high sensitivity and specificity, required for timely diagnosis and better treatment, the diagnostics industry has witnessed the emergence of point of care diagnostic solutions. In addition, the rising incidence of cardiovascular disorders, metabolic disorders and infectious diseases have resulted in prompt identification and frequent monitoring, thus amplifying the need for convenient and rapid point of care diagnostic tools. The point of care tests are widely used for the diagnosis of diseases, such as chikungunya, COVID-19, dengue, hepatitis, malaria, pneumonia, and tuberculosis.

Point of care diagnostics or bedside diagnostics offer various advantages including faster diagnostic speed, lower costs, higher efficiency and on-site detection ability. The market leaders including Abbott, Danaher, Siemens Healthineers, bioMérieux, Thermo Fisher Scientific, Roche and Quidel are consistently engaged in efforts to innovate in assay formats, developing better biosensors, and bioanalytical platforms to expedite the diagnosis process.

Innovations in device miniaturization, biosensors, microfluidics, and connectivity have enabled the development of accurate, user-friendly, and portable diagnostic devices suitable for point-of-care use. The ability of POCD testing devices to shorten hospital stays, streamline workflows, and minimize the need for follow-up visits can contribute to overall cost savings in the healthcare system.

Point of Care Diagnostics Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	$ 1.98 Billion
Market Size 2035	$ 5.29 Billion
CAGR (Till 2035)	10.3%

The point of care diagnostics market analysis also features the distribution of the current and forecasted opportunity within the point of care diagnostics domain across various segments, such as target disease indication, type of technology and geographical regions.

We have created three market forecast scenarios, conservative, base and optimistic, to account for future uncertainties in key parameters and enhance the robustness of our model. These scenarios represent different tracks of the industry's evolution.

The rising prevalence of disease indications, such as diabetes, cardiovascular disorders and respiratory disorders have necessitated early detection, facilitated via point of care detection through convenient at-home or on-site diagnostics. The market leaders are also developing tests for newer indications. In April 2024, Abbott received FDA approval for i-STAT TBI cartridge, which is a whole blood based POCD to be used by the patients bedside to assess traumatic brain injury (TBI), moving the diagnosis of TBI beyond laboratory settings.

What are the Recent Developments in the Point of Care Diagnostics Market?

Several recent developments have taken place in the global point of care and rapid diagnostics market, and we outline some of these below. These developments, even if they arose after our market report’s release, support the overall point of care diagnostics market trends detailed in our analysis.

• In February 2026, Abram Scientific secured $11.75M in Series A funding led by Octapharma AG. The investment supports development of the portable CoagCare platform for rapid point-of-care coagulation testing in trauma and surgical settings.
• In February 2026, Athelas received FDA clearance for its CLIA-waived, AI-powered Athelas Home hematology analyzer. The point-of-care device delivers white blood cell counts and neutrophil percentages from fingerstick samples in minutes for use in clinics, pharmacies, and home settings.
• In February 2026, LEX Diagnostics gained FDA clearance and CLIA waiver for the VELO system, a rapid molecular diagnostics platform. It provides PCR results for respiratory pathogens in under 10 minutes from swabs, enabling point-of-care deployment in the US.
• In February 2026, QuidelOrtho signed a supply agreement to broaden its global immunoassay portfolio with advanced analyzer platforms and assays. This enhances point-of-care diagnostic capabilities for expanded international market access.
• In November 2025, Sapphiros entered into a collaboration with Roche granting access to its $1B potential instrument-free multiplex molecular platform for affordable point-of-care testing with lab-quality results.

Point of Care Diagnostics Market Segmentation Insights

The market research report presents an in-depth analysis of the various point of care diagnostics companies, across different segments, as defined in the table below:

Point of Care Diagnostics Market: Market Segmentations

Market Segmentations	Details
Target Disease Indication	Chikungunya COVID-19 Dengue Ebola Hepatitis HIV/AIDS Influenza Malaria Pneumonia Tuberculosis Zika
Type of Technology	Lateral Flow Assay Molecular Diagnostics Fluorescence Immunoassay Solid Phase Assay Other Technologies
Geographical Regions	North America Europe Asia-Pacific Latin America Middle East and North Africa Rest of the World

COVID-19 pandemic fueled the demand for POC testing. In addition, the escalating occurrence of infectious diseases including HIV, malaria, tuberculosis demanded the need for rapid and accessible diagnostic tools for quick diagnosis, treatment and prevention.

Industry Experts on Point of Care Diagnostics Market

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Founder and CEO, Small Company in the US
• Chief Executive Officer, Small Company in the US
• Managing Director, Mid-sized Company in India
• Director of Business Development, Mid-sized Company in the US
• Business Development Manager, Mid-sized Company in Singapore

Early Mpox detection and disease surveillance urgently require point-of-care tests. In 2025, Professor Pantelis Georgiou, Co-Founder of ProtonDx, stated, “At ProtonDx, we are transforming point-of-care testing with rapid, affordable multi-pathogen diagnostic technology. Dragonfly can fit in your backpack and travel anywhere. It addresses the requirements for rapid molecular grade detection of mpox, removing the need to send a sample off to a lab.”

How is the Point of Care Diagnostics Market Segmented?

Point of Care Diagnostics Market Share by Target Disease Indication: Hepatitis Holds the Largest Share

• Point of care diagnostics / testing market is segmented into various target indications, including chikungunya, COVID-19, dengue, Ebola, hepatitis, HIV/AIDS, influenza, malaria, pneumonia, tuberculosis, and zika. Notably, hepatitis segment captures the majority of the market share and this trend is unlikely to change in the future as well.
• The market for Ebola virus will grow at a higher CAGR of 26.6% owing to the rising incidence of infectious diseases and the need for rapid testing during outbreaks.

Point of Care Diagnostics Market Share by Type of Technology: Lateral Flow Assay will be Dominant during the Forecast Period

• In terms of type of technology, the point of care diagnostics industry size is segmented into lateral flow, molecular diagnostics, fluorescence immunoassay, solid phase, and others. Lateral flow assays capture the majority share (~ 80%) in 2025.
• The point of care market for molecular diagnostics is likely to grow at a higher CAGR of 27%, signifying a higher demand and adoption of these devices owing to their ability to offer rapid results, lower costs and better outcomes.

Point of Care Diagnostics Market Share by Geographical Regions: Asia-Pacific to Propel in the Point of Care Diagnostics Sector in the Coming Years

• The market for point of care diagnostics is distributed across various geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World.
• According to our projections, North America will capture the majority (27%) of the market share in 2025, and this trend is unlikely to change in the future.
• However, considering the high prevalence of infectious diseases in the region, the market in Asia-Pacific will grow at a relatively faster pace (14.5%) in the foreseen future.

Point of Care Diagnostics Market: Report Deliverables

Report Deliverables	Details
Analytical Insights Covered	Market Landscape Partnerships and Collaborations Analysis Key Acquisition Targets Start-up Ecosystem Analysis Market Sizing and Opportunity Analysis
Strategic Insights Covered	Executive Infographic Summary Executive Insights
Key Point of Care Diagnostics Companies	Aduro Biotech Bristol-Myers Squibb Eisai GlaxoSmithKline ImmuneSensor Therapeutics Merck Noxopharm Spring Bank Pharmaceuticals Synlogic Avammune Therapeutics ImmuneSensor Therapeutics Nimbus Therapeutics Sirenas STINGINN STipe Therapeutics (Full list of 150+ companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

What are the Major Takeaways of Point of Care Diagnostics Market?

The “Point of Care Diagnostics Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, partnership and collaboration analysis, start-up ecosystem analysis, key acquisition targets, market sizing and future opportunities for the point of care diagnostics companies, during the forecast period.

How is the Competitive Landscape of Point of Care Diagnostics Industry Fragmented?

The current market landscape features a mix of small and mid-sized firms, and established players. At present, ∼280 players are developing POCDs for multiple indications; majority of these developers are based in developed geographies and most of these are small firms / start-ups, and mid-sized players.

Around 95% of the point-of-care diagnostics are tests, followed by device / platforms (5%). Further, nearly 85% of the aforementioned products use lateral flow technology for effective diagnosis, followed by those based on molecular diagnostics (7%) and fluorescence immunoassay (2%).

What is the Future Opportunity for the Point of Care Diagnostics Companies?

The global point of care diagnostics market size is likely to be $ 1.98 billion in 2025 and will reach $ 5.29 billion by 2035.

At present, a considerable share (28%) of the market (in terms of revenues from product sales) is captured by products intended for the diagnosis of hepatitis, followed by those designed for pneumonia (25%), dengue (24%) and malaria (18%).

Safety concerns and the need for product quality assurance are necessitating increased testing. Further, the domain has witnessed a growing shift towards decentralized healthcare models, bringing diagnostics closer to patients in homes, primary care settings, and remote areas with limited access to central labs.

Which Region Holds the Largest Share of the Point of Care Diagnostics Market?

North America and Europe are Leading the Market

North America and Europe are likely to dominate the global point of care diagnostic industry in 2035. Interestingly, North America features the majority of the point of care testing companies (35%).

Asia-Pacific: An Emerging Growth Spot

The market in Asia-Pacific is likely to grow at a relatively high CAGR (14.5%), during the forecast period till 2035. This is due to the high prevalence of infectious diseases in this region.

According to the World Health Organization (WHO), the big three infectious diseases, namely human immunodeficiency virus / acquired immunodeficiency syndrome (HIV / AIDS), malaria and tuberculosis (TB), are reported to be the cause of approximately 2.5 million annual fatalities worldwide. A significant burden of these indications is contributed by Asia-pacific.

What are the Key Drivers of Point of Care Testing Market?

The benefits offered by point of care diagnostics including rapid diagnosis, easy accessibility and cost-effectiveness compared to laboratory diagnostics has driven this market for a long period of time. This is in addition to the growing incidence of chronic and infectious diseases where POCD have been helpful, such as during the COVID-19 pandemic.

However, the future growth in this market will be driven by integration of next-generation technologies such as smartphone connectivity, cloud services (cloud-based data management), and AI-driven analytics will enhance the capabilities and accessibility of POCD. In February 2025, Avitia launched its AI-powered platform that allows rapid and point of care testing for cancer mutations.

Furthermore, the development of POCD for cancer will also be a key driver for the market over the forecast period. Examples of some approved point of care diagnostics tests for cancer include IDL Diagnostics’ UBC® Rapid for urine-based bladder cancer detection, and at-home PSA testing kits for prostate cancer. Companies like Owlstone Medical are also working on the development of breath biopsy tests for lung cancer.

Key Market Trends in Point of Care Diagnostics Market

Will Rising Partnerships and Collaborations Foster Progress and Innovation?

Point of care diagnostics service providers established several partnerships with other stakeholders to enhance their portfolio offerings. Notably, in the last five years, companies based in North America and Europe have inked most of these partnerships to strengthen their point of care testing capabilities.

It is worth highlighting that majority of the deals signed in this domain are instances of distribution and supply agreements, followed by product development and commercialization agreements. Such agreements help expand access to the tests to the consumers across various settings such as homes or clinics. In October 2024, NOWDiagnostics collaborated with Labcorp to distribute its First To Know® Syphilis Test in professional and healthcare settings in the US.

From the Author’s Desk

Author’s View on Point of Care Diagnostics Market

Point of care diagnostics have revolutionized medical diagnosis by providing rapid and timely results, enabling faster clinical decision-making and improved patient management across diverse healthcare settings. Technological breakthroughs, such as advances in microfluidics and nucleic acid amplification technologies will lead to faster, more accurate molecular tests for infectious diseases and genetic markers directly at the point of care, thereby reducing reliance on central laboratories

Glossary

• Point of Care Tests: Healthcare providers perform point of care tests at the bedside, providing timely diagnostic information to the patient and thus contributing to more efficient and patient-centered care.
• Molecular Diagnostics: Laboratories use molecular diagnostics tests to examine molecules, such as DNA, RNA, and proteins, within a biological sample. These tests offer insights into a patient’s health at the cellular and genetic level by detecting specific genetic material.
• Lateral Flow Assay: It is a simple diagnostic device used for identifying the presence or absence of a target substance (analyte) in a liquid sample.
• Fluorescence Immunoassay: It is an analytical technique that uses fluorescence to detect the concentration of analytes such as drugs, hormones, proteins in a sample.
• Microfluidics: It is the study of nature of fluids through micro-channels having dimensions at microscale. The field includes molecular biology, molecular analysis and microelectronics.

Frequently Asked Questions

Question 1: What is the point of care diagnostics?

Answer: Point of care diagnostics allows healthcare providers to quickly identify analytes close to the patient, facilitating better disease diagnosis, monitoring, and management.

Question 2: How big is the POC diagnostics market?

Answer: The point of care diagnostics market size is estimated to be worth USD 1.98 billion in 2025.

Question 3: What is the outlook for the point of care diagnostics market?

Answer: The point of care diagnostics industry is anticipated to reach USD 5.29 billion by 2035.

Question 4: What is the projected point of care diagnostics market growth?

Answer: The market for point of care diagnostics is expected to grow at a compounded annual growth rate (CAGR) of 10.3% during the forecast period.

Question 5: How big is the market for point of care diagnostics in North America?

Answer: North America is expected to capture 27% point of care diagnostics market share in 2025.

Question 6: Who are the leading point of care diagnostic companies?

Answer: Aduro Biotech, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, ImmuneSensor Therapeutics, Merck, Noxopharm, Spring Bank Pharmaceuticals, Synlogic, Avammune Therapeutics, Curadev, Nimbus Therapeutics, Sirenas, STINGINN and STipe Therapeutics.

Question 7: How many products are presently being evaluated by players engaged in the point of care diagnostics market?

Answer: Presently, players engaged in the point of care diagnostics industry are evaluating close to 1,600 products.

Question 8: How many partnership deals have been inked by stakeholders engaged in the point of care sector?

Answer: Stakeholders engaged in the market have signed more than 105 partnership deals in the last few years.